[go: up one dir, main page]

DK1187635T3 - Anæstetisk formulering der omfatter en NMDA-antagonist og en alfa-2 adrenerg agonist - Google Patents

Anæstetisk formulering der omfatter en NMDA-antagonist og en alfa-2 adrenerg agonist

Info

Publication number
DK1187635T3
DK1187635T3 DK00940519T DK00940519T DK1187635T3 DK 1187635 T3 DK1187635 T3 DK 1187635T3 DK 00940519 T DK00940519 T DK 00940519T DK 00940519 T DK00940519 T DK 00940519T DK 1187635 T3 DK1187635 T3 DK 1187635T3
Authority
DK
Denmark
Prior art keywords
alpha
adrenergic agonist
nmda antagonist
anesthetic formulation
formulation
Prior art date
Application number
DK00940519T
Other languages
English (en)
Inventor
Nicholas Peter Imperial Franks
Mervyn Imperial Coll Scho Maze
Original Assignee
Protexeon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10855216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1187635(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protexeon Ltd filed Critical Protexeon Ltd
Application granted granted Critical
Publication of DK1187635T3 publication Critical patent/DK1187635T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK00940519T 1999-06-11 2000-06-09 Anæstetisk formulering der omfatter en NMDA-antagonist og en alfa-2 adrenerg agonist DK1187635T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9913677.2A GB9913677D0 (en) 1999-06-11 1999-06-11 Formulation
PCT/GB2000/002271 WO2000076545A1 (en) 1999-06-11 2000-06-09 Anaesthetic formulation comprising an nmda-antagonist and an alpha-2 adrenergic agonist

Publications (1)

Publication Number Publication Date
DK1187635T3 true DK1187635T3 (da) 2004-06-21

Family

ID=10855216

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00940519T DK1187635T3 (da) 1999-06-11 2000-06-09 Anæstetisk formulering der omfatter en NMDA-antagonist og en alfa-2 adrenerg agonist

Country Status (14)

Country Link
US (1) US6562855B1 (da)
EP (1) EP1187635B1 (da)
JP (1) JP2003529541A (da)
AT (1) ATE259658T1 (da)
AU (1) AU778671B2 (da)
CA (1) CA2376916C (da)
DE (1) DE60008374T2 (da)
DK (1) DK1187635T3 (da)
ES (1) ES2215678T3 (da)
GB (2) GB9913677D0 (da)
PT (1) PT1187635E (da)
RU (1) RU2244558C2 (da)
WO (1) WO2000076545A1 (da)
ZA (1) ZA200110116B (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812545B1 (fr) * 2000-08-03 2003-03-28 Air Liquide Sante Int Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
GB0209998D0 (en) * 2002-05-01 2002-06-12 Protexeon Ltd Use
DK1515732T3 (da) 2002-06-12 2009-05-11 Air Liquide Deutschland Gmbh Cerebral protektion med en xenonholdig gas
EP1521598A1 (de) * 2002-07-05 2005-04-13 Air Liquide Deutschland GmbH Xenon enthaltendes adjuvans
WO2004052337A2 (de) * 2002-12-06 2004-06-24 Michael Georgieff Nasale pharmazeutische präparation enthaltend eine lipophile flüssige oder gasförmige wirksubstanz
CA2542412A1 (en) * 2003-10-21 2005-05-06 Aga Ab Use of xenon for the prevention of programmed cell death
US7795263B2 (en) * 2008-07-08 2010-09-14 Wildlife Laboratories, Inc. Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals
US20100022574A1 (en) * 2008-07-28 2010-01-28 EndogenX, Inc. Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist
US20110244058A1 (en) * 2008-08-01 2011-10-06 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
EP2320911B1 (en) 2008-08-01 2014-10-08 Eye Therapies LLC Vasoconstriction compositions and methods of use
NZ596976A (en) * 2009-05-15 2014-05-30 Recro Pharma Inc Sublingual dexmedetomidine compositions and methods of use thereof
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
US20110152271A1 (en) * 2009-12-17 2011-06-23 Gerald Horn Compositions and methods for ophthalmic delivery of nasal decongestants
JP2013516482A (ja) * 2010-01-08 2013-05-13 レクロ・ファーマ，インコーポレーテッド 局所経皮用デクスメデトミジン組成物およびそれらの使用方法
US20130029989A1 (en) * 2010-04-15 2013-01-31 The Royal Institution For The Advancement Of Learning/Mcgill University Topical treatments for pain
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
JP6268100B2 (ja) 2011-12-11 2018-01-24 レクロ・ファーマ，インコーポレーテッド 鼻腔内デクスメデトミジン組成物およびその使用方法
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
EP4082552A1 (en) 2013-03-15 2022-11-02 The Board of Regents of the University of Texas System Liquids rich in noble gas and methods of their preparation and use
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
KR20180095732A (ko) 2013-10-07 2018-08-27 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물
CN106456561B (zh) 2013-10-07 2020-02-28 帝国制药美国公司 使用右旋美托咪啶经皮组合物治疗注意力缺陷多动症、焦虑症和失眠症的方法和组合物
CA2924231C (en) 2013-10-07 2018-04-03 Teikoku Pharma Usa, Inc. Dexmedetomidine transdermal delivery devices and methods for using the same
RU2557882C1 (ru) * 2014-07-08 2015-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО АГМА Минздрава России) Способ проведения премедикации при плановом хирургическом лечении
WO2017139382A1 (en) * 2016-02-08 2017-08-17 The Texas A&M University System Combination of adjuvant drugs esketamine and brimonidine for medical treatments
WO2023287726A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of cancer using botulinum toxin and nitrous oxide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859685A (en) * 1986-08-13 1989-08-22 Boc, Inc. Anesthetic composition and method of using the same
US5605911A (en) * 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
JP2000500020A (ja) 1995-11-13 2000-01-11 コミサリア・ア・レネルジー・アトミーク 正十二面体様アデノウイルス・タンパク質複合体、それを含む組成物、及びその使用方法
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
FR2787713A1 (fr) 1998-12-23 2000-06-30 Johan Huysman Composition en tant que medicament et utilisation d'une telle composition pour l'obtention d'un medicament destine a l'anesthesie, notamment medicament analgesique
DE19910986C2 (de) 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist

Also Published As

Publication number Publication date
DE60008374T2 (de) 2004-12-09
PT1187635E (pt) 2004-07-30
US6562855B1 (en) 2003-05-13
DE60008374D1 (de) 2004-03-25
GB0014165D0 (en) 2000-08-02
GB2352633B (en) 2002-04-17
ATE259658T1 (de) 2004-03-15
EP1187635B1 (en) 2004-02-18
JP2003529541A (ja) 2003-10-07
EP1187635A1 (en) 2002-03-20
CA2376916A1 (en) 2000-12-21
AU5544400A (en) 2001-01-02
RU2244558C2 (ru) 2005-01-20
CA2376916C (en) 2010-09-21
AU778671B2 (en) 2004-12-16
ZA200110116B (en) 2003-07-23
GB9913677D0 (en) 1999-08-11
ES2215678T3 (es) 2004-10-16
WO2000076545A1 (en) 2000-12-21
GB2352633A (en) 2001-02-07

Similar Documents

Publication Publication Date Title
DK1187635T3 (da) Anæstetisk formulering der omfatter en NMDA-antagonist og en alfa-2 adrenerg agonist
NO20024309D0 (no) Intradermal penetreringsmidler for topikal lokal anestetisk administrering
ATE345112T1 (de) Opioid enthaltende arzneiform gegen missbrauch
EE9700192A (et) Peroraalne farmatseutiline annusvorm, mis sisaldab prootonpumba inhibiitorit ja antatsiidainet või alginaati
SI1414451T1 (sl) Formulacije opioidnega agonista s sproščanja sposobnim in sekvestriranim antagonistom
AU5984801A (en) Local anesthetic methods and kits
EE9700195A (et) Peroraalne farmatseutiline annusvorm, mis sisaldab prootonpumba inhibiitorit ja prokineetilist ainet
EE9700194A (et) Peroraalne farmatseutiline annusvorm, mis sisaldab prootonpumba inhibiitorit ja NSAID
DE60044041D1 (de) Exendine zur Glucagon Suppression
DK1191926T3 (da) Ny omeprazol- og (S)-omeprazolformulering
CY1115869T1 (el) Χρηση ανταγωνιστων του υποδοχεα τυπου 1 της αγγειοτενσινης ii για την προληψη του διαβητη
EA199700230A1 (ru) Дозирующий ингалятор для дипропионата беклометазона
MY129356A (en) Electrospun pharmaceutical compositions
NO20004215L (no) Et farmasøytisk preparat som omfatter en angiotensin II type 2-reseptoragonist, og anvendelse derav
GEP20063996B (en) Aripiprazole complex formulation and use thereof
ES2157881T3 (es) Metanosulfonato de paroxetina.
DE60111265D1 (de) Pharmazeutische zusammensetzungen mit nmda-rezeptor-agonist
ATE292453T1 (de) Antivirale arznei
AU2001287698A1 (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
ES2148493T3 (es) Nuevos compuestos con efecto analgesico y anestesico local.
ATE258045T1 (de) Verfahren zu herstellung von pulverförmigen solubilisationshilfsstoffen für feste pharmazeutische darreichungsformen
NO20010537D0 (no) Farmasöytiske preparater omfattende ibuprofen og domperidon
ATE297760T1 (de) Pharmazeutische zusammensetzungen enthaltend terbinafin
CY1108502T1 (el) Ελεγχομενης-αποδεσμευσης συνθεσεις οι οποιες περιεχουν οπιοειδη αγωνιστη και ανταγωνιστη
AU2002235767A1 (en) Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists